Skip to contentB
Biolargo, Inc.
B
BLGOBiolargo, Inc. Q2 2021 · 10-Q
Revenue$464.00K$464.00K+11.0% vs Q2 2020 Net Income-$1.79M-$1.79MN/M vs Q2 2020 EPS Diluted-$0.01-$0.01N/M vs Q2 2020 Gross Profit$201,000−7.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biolargo, Inc. · CIK 880242 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,209,000N/M Margins · derivedGross margin43.3%−8.6 pt vs Q2 2020
Operating margin-366.8%+112.9 pt vs Q2 2020
Net margin-385.8%+260.2 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 16, 2021 · 47 d after period end